Literature DB >> 3261498

In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA).

M Etievant1, B Leluc, B David.   

Abstract

A synthetic dipeptide, magnesium salt of N-acetyl-L-aspartyl-glutamic acid (NAAGA) identical to a natural dipeptide found as traces in cerebral tissues of mammalian brains, was shown to inhibit, in vitro, the hemolytic activity of both classical and alternate pathways complement; the required concentration of NAAGA was 2 to 10 mM. Cross immuno electrophoretic analysis demonstrated an inhibition of C3 cleavage by both classical and alternate pathway C3 convertases with 24 mM NAAGA. As expected, if C3 convertases were really the target of inhibition, the release of highly inflammatory C3a, C5a fragments scored by R.I.A. was impaired when complement was incubated with activators of classical and alternate pathways. Such a low molecular weight dipeptide, quite atoxic and inhibiting the complement dependent cytotoxicity and release of phlogistic by-products could be interesting for pharmacological manipulation of complement activation in inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261498     DOI: 10.1007/bf01968092

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  INHIBITION OF THE C'-1 COMPONENT OF COMPLEMENT BY AMINO ACIDS.

Authors:  F B TAYLOR; H FUDENBERG
Journal:  Immunology       Date:  1964-07       Impact factor: 7.397

2.  Studies on the distribution of N-acetyl-L-aspartic acid in brain.

Authors:  H H TALLAN
Journal:  J Biol Chem       Date:  1957-01       Impact factor: 5.157

3.  N-Acetyl-L-aspartic acid in brain.

Authors:  H H TALLAN; S MOORE; W H STEIN
Journal:  J Biol Chem       Date:  1956-03       Impact factor: 5.157

4.  Capacity of complement c3 phenotypes to bind on to mononuclear cells in man.

Authors:  H Arvilommi
Journal:  Nature       Date:  1974-10-25       Impact factor: 49.962

5.  Inhibition of the classical and alternative pathways by amino acids and their derivatives.

Authors:  Y Takada; Y Arimoto; H Mineda; A Takada
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

6.  Inflammatory mediators released by complement-derived peptides.

Authors:  H Bult; A G Herman
Journal:  Agents Actions       Date:  1983-08

7.  N-acetylaspartylglutamate: an endogenous peptide with high affinity for a brain "glutamate" receptor.

Authors:  R Zaczek; K Koller; R Cotter; D Heller; J T Coyle
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

Review 8.  Pharmacological manipulation of complement system.

Authors:  S S Asghar
Journal:  Pharmacol Rev       Date:  1984-12       Impact factor: 25.468

9.  Complement and clinical intervention.

Authors:  J Watkins
Journal:  Ann Fr Anesth Reanim       Date:  1985
  9 in total
  4 in total

1.  Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).

Authors:  J Feuillard; F Maillet; P Goldschmidt; L Weiss; M D Kazatchkine
Journal:  Agents Actions       Date:  1991-03

2.  N-acetyl-aspartyl glutamic acid (NAAGA) topical eyedrops in the treatment of giant papillary conjunctivitis (GPC).

Authors:  F Meijer; K Pogany; J H Kok; A Kijlstra
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

3.  Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.

Authors:  A Leonardi; D Bremond-Gignac; M Bortolotti; D Violato; P Pouliquen; L Delval; J M Grouin; I A Fregona
Journal:  Br J Ophthalmol       Date:  2007-06-21       Impact factor: 4.638

4.  Modulation of allergen-induced nasal symptoms and mediator release by treatment with N-acetyl-aspartyl-glutamate (ZY15106).

Authors:  A Miadonna; M Cottini; C Candiani; A Tedeschi
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.